Division of Alphaeon Corp.
Latest From Evolus Inc.
AbbVie is buying Allergan for its product sales, both to increase its own revenues and to fund future R&D and business development, so Allergan's Q2 gains are good news.
Shares of Korea's Medytox fell on suspicions that it supplied botulinum toxin to local hospitals before the product's approval in 2006. The concerns add to other manufacturing issues that have been denied by the company, which pointed to a rival as the possible source amid an ongoing legal battle over the strain used in the product.
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish
Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Alphaeon Corp.
- Senior Management
David Moatazedi, Pres. & CEO
Lauren Silvernail, CFO & EVP, Corp. Dev.
J. Christopher Marmo, PhD, COO
Rui Avelar, MD, Head, R&D & CMO
Michael Mazen Jafar, Chief Mktg. Officer
- Contact Info
Phone: (949) 284-4555
520 Newport Center Dr.
Newport Beach, CA 92660
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.